1. Home
  2. KXIN vs BDRX Comparison

KXIN vs BDRX Comparison

Compare KXIN & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KXIN

Kaixin Auto Holdings

HOLD

Current Price

$6.61

Market Cap

5.4M

ML Signal

HOLD

Logo Biodexa Pharmaceuticals plc

BDRX

Biodexa Pharmaceuticals plc

HOLD

Current Price

$2.45

Market Cap

4.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KXIN
BDRX
Founded
2015
2000
Country
China
United Kingdom
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4M
4.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KXIN
BDRX
Price
$6.61
$2.45
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
339.2K
2.8M
Earning Date
11-26-2019
09-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$95,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.94
$2.22
52 Week High
$55.50
$92.00

Technical Indicators

Market Signals
Indicator
KXIN
BDRX
Relative Strength Index (RSI) 70.18 39.06
Support Level $4.87 $2.22
Resistance Level $6.20 $2.63
Average True Range (ATR) 0.80 0.51
MACD 0.16 -0.13
Stochastic Oscillator 90.25 4.50

Price Performance

Historical Comparison
KXIN
BDRX

About KXIN Kaixin Auto Holdings

Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.

About BDRX Biodexa Pharmaceuticals plc

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.

Share on Social Networks: